Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
do you think I write so well?
LOL
it's only the answer!
a part
TMDI MC 58 Mil
Cash flow near 45/48 mil after M4
After problem with previus OEM
manufacturing and supply agreement with Benchmark!
Waiting patiently for IDE!
ISRG trading at 53 times forward 12-months earnings estimates, vs 5-yr avg of about 46X, per Refinitiv Datastream.
Medtronic (MDT.N), Abbot Laboratories (ABT.N), and Stryker (SYK.N) have forward EV-to-EBITDA ratios ranging from 16 to 20.
there is a why!
OTB
We are heading north even though it is difficult to see! Here I see a glow at the end of the tunnel. The bad news is all on the table ;D!
Is it time you started covering?
it is true now my road is narrow and dark and it seems that it leads you nowhere ... but even you are not in good shape, are you sure that you are not climbing the ladder of the chicken coop?
...Paul Cataford our interim President and CEO has discussed on several platforms where the company is now, after having to announce the product delay to marketing and the subsequent resignation of our Prior President and CEO. We have shared as much as we can about our relationship with Medtronic, the world’s leading medical technology company, and the recently announced success of accomplishing our milestone. We have stated that we are committed to transparency, and we will continue to share news when we have it as soon as we are able.
Again, all that we can share is in the public domain, so I refer you to the documents and presentations that outline where we are and where we are going...
right!
time to go north!
we would need one with a swollen wallet!
the only thing keeping me here is the shareholders of Tmdi!
the best!
we will sell our leather dearly
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
North Carolina State University
https://www.sciencedaily.com/releases/2022/01/220126122501.htm
Johns Hopkins University
https://www.sciencedaily.com/releases/2022/01/220126143954.htm
https://www.ldmicro.com/profile/tmdi/insiders
As if to say I feel the smell of burning on the subject!
There are personal reasons! It seems that they give goodies ...
Thinking badly makes me say that it is a good excuse to bring down the price but perhaps there are serious personal reasons ...
I think I'll add
The appointment of Mr. Milford follows the resignation of Douglas Satzman as the President and Chief Executive Officer of the Company for personal reasons effective as of the same date.
In connection with Mr. Satzman’s departure, the Company expects to enter into a severance and release agreement with Mr. Satzman, providing for a severance package with Mr. Satzman, subject to Mr. Satzman executing a general release in favor of the Company, resigning as a director of the Company and otherwise complying with the terms of the severance and release agreement. In connection therewith, the Board has appointed Mr. Milford as a member of the Board with an initial term expiring at the Company’s 2022 Annual Meeting of Stockholders, contingent upon and effective immediately following Mr. Satzman’s resignation as a director.
Why did Dr. Advincula leave the SAB?
We need a logical answer! it happened a few days after this
https://ir.titanmedicalinc.com/news-events/press-releases/detail/337/titan-medical-announces-expansion-of-surgeon-advisory-board
https://books.google.it/books?id=BxtNEAAAQBAJ&pg=PA759&lpg=PA759&dq=Robotic+Surgery:+Advancements+and+Inflection+Points+in+the+Field+of+Gynecology&source=bl&ots=6pCmHVqPd3&sig=ACfU3U2NGtEA_nZOIE9pXyS1LggovgS1Xg&hl=it&sa=X&ved=2ahUKEwjBs57m5MT1AhUl7rsIHVnVCmgQ6AF6BAgDEAM#v=onepage&q=Robotic%20Surgery%3A%20Advancements%20and%20Inflection%20Points%20in%20the%20Field%20of%20Gynecology&f=false
https://www.jmig.org/action/showPdf?pii=S1553-4650%2818%2930601-0
What did he say about Sport?
Conclusions: While continued evolution of the prototype is needed, as well as validation in its ability to complete a surgical procedure, applica- tion of this new robot to successfully perform all the necessary tasks is demonstrated
https://www.columbiaobgyn.org/titan-medical-partners-columbia-university-medical-center-sport-feasibility-and-validation-studies are they still partners?
McNally 11 november:
And as they say, we’re working with our Surgeon Advisory Board, led by Dr. Arnold Advincula of Columbia University Medical Center, who is our medical advisor to develop the right sequence of curriculum, one to train for performing the IDE studies or clinical studies and then ultimately a program that can be rolled out upon marketing clearance to train an expanding group of surgeons. So that’s first question.
Second, with respect to license technologies, we will continually seek opportunities to license our IP and knowhow where it makes sense, as we did with the Medtronic development and license agreements where we’ve retained rights to all of that technology to implement in the Enos system. There may be other opportunities for us to out license, as well as licensing technology from other companies that would be complementary to what we have in terms of the Enos system.
moral of the broad bean!
many have fewer shares than before!
McNally spilled the beans!
IMO Now that the future is bitterly clear on the actual development times I think fat entry is possible!
and do you think they are sorry?
I was expecting some news for this:
Ebopiprant for Treatment of Preterm Labor: Preparations are ongoing to initiate a Phase 2b clinical study in Q4:21. The Phase 2b dose ranging study will build on the recently announced PROLONG Phase 2a proof-of-concept study, which demonstrated early clinical efficacy and safety in pregnant women with spontaneous preterm labor. Given ebopiprant is currently the only known product in development for this indication and based on its innovative mechanism of action and positive topline data, the Company plans to discuss with European regulators a possible accelerated registration program based on a Phase 2b/3 adaptive design. In parallel with development of ebopiprant in Europe and Asia, the Company is also actively evaluating the regulatory strategy for ebopiprant development in the United States, where there are currently no FDA-approved tocolytic medications available for treatment of preterm labor.
likely something changed after this:
https://www.organon.com/news/organon-and-obseva-enter-global-license-agreement-to-develop-and-commercialize-ebopiprant-obe022-an-investigational-agent-being-evaluated-as-a-first-in-class-treatment-for-preterm-labor/
I think these latest requests are a modification or evolution of this:
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=29&f=G&l=50&co1=AND&d=PG01&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
ther's in place an opportunity bys trade secrets
As the shorts often remind us, they paid little for the milk,
I wonder why?
Very little! Why?
What did McNally want when he promised the milk? What was he looking for?
one more degree! Everyone would like to switch from MDT to RBOT
LOL
So!
they kept what was good and went where MDT is!
Their comprehensive engineering, manufacturing and supply chain capabilities are uniquely suited to design and produce high-quality, complex electromechanical medical systems. Among engineering and manufacturing companies, Benchmark is also differentiated by its expertise in the design and manufacture of visualization systems. This potentially adds additional value to our relationship with core expertise in a technology that is strategic to our Enos system.
Medtronic technical leader who initiated and led the Medtronic Robotics program left
very interesting!
remains this
https://www.linkedin.com/in/bpcash
The Enos surgical system is based on proprietary technology protected by a broad patent portfolio, trade secrets and know-how.
How many secrets playing with the asses of others!
Surely it is the time of pain
difficult to see the way to gain
Diversify investor base with an opportunity to include long-term institutional investors
https://www.obseva.com/pressrelease-detail/?pr=4786
Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months-
Ongoing for up to an additional 6 months
https://clinicaltrials.gov/ct2/show/NCT04335591
Where will they decide to take it?
it depends on the fair value of things
TMDI 75 MIL (40/45 mil cash)
ISRG 127 BIL
https://ir.titanmedicalinc.com/news-events/press-releases/detail/342/titan-medical-to-participate-in-h-c-wainwright-bioconnect
curious to see if there will be any changes in the strategy
Paul Cat give us the road!
New IHU variant with more omicron mutations, reported from France.
Until they invent a cure or a vaccine that works on the variants, tracking is key to stemming!
looks bad for the shorts!
just added some!
I think it is better for everyone to take shares on the market!
ONLY bookings from the website:
Summary for 2022-01-03
JFK: 1296/1296 (100%)
BOS_E: 234/234 (100%)
BOS_C: 252/252 (100%)
EWR_B: 280/280 (100%)
EWR_C: 185/185 (100%)
PHX: 108/108 (100%)
DEN: 275/275 (100%)
SLC: 201/275 (73%)
IAH: 275/275 (100%)
DCA: 275/275 (100%)
IAD: 222/222 (100%)
SEA: 185/185 (100%)
SFO: 148/148 (100%)
ATL_E: 259/259 (100%)
=====================
Total = 4195 of 4269 (98%)
You feel it too!
Something comes out soon!
I think the firefighters have tamed the fire!
The latest patent is a fact!
https://www.globenewswire.com/news-release/2022/01/03/2359807/0/en/ObsEva-to-Present-at-the-H-C-Wainwright-BioConnect-2022-Conference.html
Oh good!
They want appropriate showcase to comment on the data!
IMO